Patents by Inventor William Holmes
William Holmes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12194188Abstract: A rack for sanitizing or cleaning medical or personal protective equipment is claimed herein. The rack has at least two stringers that run the length of the rack. The rack has at least two vertical grates that are spaced apart from each other along the stringers. The spacing between the grates will be sufficient such that a standard respiratory mask (e.g. N95) may be placed between two adjacent grates and be held in a vertical orientation.Type: GrantFiled: April 1, 2021Date of Patent: January 14, 2025Assignee: University of Louisiana at LafayetteInventors: Mark E. Zappi, William Holmes, Andrei Chistoserdov, Wayne Sharp, Alex Zappi, Rafael Hernandez, William Chirdon, Don Begneaud, Thomas Broussard
-
Publication number: 20240307436Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: ApplicationFiled: November 8, 2023Publication date: September 19, 2024Applicant: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20240148784Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: ApplicationFiled: November 8, 2023Publication date: May 9, 2024Applicant: Astellas Institute for Regenerative MediceInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilnr
-
Patent number: 11850261Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: GrantFiled: October 9, 2019Date of Patent: December 26, 2023Assignee: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20230093562Abstract: This invention is a novel method to thermally process wet WWTP sludges, including biosolids, so that they can be classified. Wet biosolids or other WWTP sludges are passed through the heating zones of one or more solar thermal systems so that the sludges are heated to a target temperature to meet the requirements for U.S. Environmental Protection Agency classification. Various catalysts are provided before the sludges enter the heating zone and within the heating zone to optimize the treatment of the sludges.Type: ApplicationFiled: September 16, 2022Publication date: March 23, 2023Applicant: University of Louisiana at LafayetteInventors: Mark E. ZAPPI, Terence Chambers, Wayne Sharp, Rafaei Hernandez, Daniel Gang, William Holmes
-
Publication number: 20220403423Abstract: The inventive biorefinery system and method accepts municipal solid waste, sewage sludges, and/or ag-wastes and processes it through three primary conversion unit operations to produce a variety of value-added products. In a preferred embodiment, the three primary conversion units are gasification, thermal depolymerization or torrefaction/pyrolysis, and biotreatment.Type: ApplicationFiled: June 22, 2022Publication date: December 22, 2022Applicant: University of Louisiana LafayetteInventors: MARK E. ZAPPI, RAFAEL HERNANDEZ, DHAN LORD FORTELA, PRASHANTH BUCHIREDDY, EMMANUEL REVELLAME, WAYNE SHARP, JOHN GUILLORY, DANIEL GANG, WILLIAM HOLMES
-
Publication number: 20220279947Abstract: A disposable plate having a base portion with a perimeter and a tab extending from the perimeter. The plate is configured to nest with a second disposable plate having a second tab and the second disposable plate is underneath the disposable plate. The tab is configured to be staggered from the second tab such that a user grabbing the tab does not grab the second tab.Type: ApplicationFiled: March 4, 2021Publication date: September 8, 2022Inventor: WILLIAM HOLMES
-
Publication number: 20220049217Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells am molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described hemin are useful for treating retinal degenerative diseases.Type: ApplicationFiled: March 29, 2021Publication date: February 17, 2022Applicant: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20210316029Abstract: A method and device for treating contaminated or potentially contaminated items is provided. The method will include the steps of placing the items in a reactor. The reactor is then sealed and ozone or ozonated gas is sent into the reactor. The items are held in the reactor long enough to complete the decontamination process. The reactor is then opened. Next there is a period of passive reaction so that the ozone can be degraded from the pores and surfaces of the items. The device provided herein includes a reactor, an ozone generator, a rack for holding said items; and a monitor for determining the level of ozone in the reactor.Type: ApplicationFiled: June 14, 2021Publication date: October 14, 2021Inventors: Mark E. Zappi, William Holmes, Andrei Chistoserdov, Wayne Sharp, Alex Zappi, Rafael Hernandez, William Chirdon
-
Publication number: 20210308312Abstract: A rack for sanitizing or cleaning medical or personal protective equipment is claimed herein. The rack has at least two stringers that run the length of the rack. The rack has at least two vertical grates that are spaced apart from each other along the stringers. The spacing between the grates will be sufficient such that a standard respiratory mask (e.g. N95) may be placed between two adjacent grates and be held in a vertical orientation.Type: ApplicationFiled: April 1, 2021Publication date: October 7, 2021Inventors: Mark E. Zappi, William Holmes, Andrei Chistoserdov, Wayne Sharp, Alex Zappi, Rafael Hernandez, William Chirdon, Don Begneaud, Thomas Broussard
-
Publication number: 20210290805Abstract: A method and device for treating contaminated or potentially contaminated items is provided. The method will include the steps of placing the items in a reactor. The reactor is then sealed and ozone or ozonated gas is sent into the reactor. The items are held in the reactor long enough to complete the decontamination process. The reactor is then opened. Next there is a period of passive reaction so that the ozone can be degraded from the pores and surfaces of the items. The device provided herein includes a reactor, an ozone generator, a rack for holding said items; and a monitor for determining the level of ozone in the reactor.Type: ApplicationFiled: March 23, 2021Publication date: September 23, 2021Inventors: Mark E. Zappi, William Holmes, Andrei Chistoserdov, Wayne Sharp, Alex Zappi, Rafael Hernandez, William Chirdon
-
Patent number: 10984393Abstract: Techniques of intelligent management of calendar items in computing systems are disclosed herein. In one embodiment, a calendar server can be configured to determine whether to accept a requested meeting utilizing a decision tree pre-configured at the server by a service provider. The decision tree contains one or more hierarchical decision nodes individually comparing one or more of parameters provided by a meeting requester to a corresponding criterion previously provided by the service provider. The calendar server can also be configured to invoke an application identified in the decision tree and provide results of the invoked application to the meeting requester in lieu of accepting the requested meeting.Type: GrantFiled: February 9, 2018Date of Patent: April 20, 2021Assignee: Microsoft Technology Licensing, LLCInventors: Anant Trivedi, William Holmes, Chandresh Kumar Jain
-
Publication number: 20210060062Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: ApplicationFiled: October 9, 2019Publication date: March 4, 2021Applicant: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Patent number: 10885065Abstract: Embodiment for identifying data convergence are presented. First and second sets of data each comprising heterogeneous data are each processed in accordance with a data clustering algorithm so as to obtain a plurality of primary and secondary data clusters, respectively, where each data cluster comprising homogeneous data. The primary and secondary data clusters are analyzed with respect to time to identify convergence of data of the first and second sets of data to first and second topics, respectively. The first and second topics are compared to determine a pattern of data convergence for the first and second data sets.Type: GrantFiled: October 5, 2017Date of Patent: January 5, 2021Assignee: International Business Machines CorporationInventors: Jonathan Dunne, Karen Forde, William Holmes, Andrew Penrose
-
Publication number: 20200113938Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: ApplicationFiled: October 9, 2019Publication date: April 16, 2020Applicant: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Patent number: 10485829Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: GrantFiled: November 17, 2010Date of Patent: November 26, 2019Assignee: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20190251518Abstract: Techniques of intelligent management of calendar items in computing systems are disclosed herein. In one embodiment, a calendar server can be configured to determine whether to accept a requested meeting utilizing a decision tree pre-configured at the server by a service provider. The decision tree contains one or more hierarchical decision nodes individually comparing one or more of parameters provided by a meeting requester to a corresponding criterion previously provided by the service provider. The calendar server can also be configured to invoke an application identified in the decision tree and provide results of the invoked application to the meeting requester in lieu of accepting the requested meeting.Type: ApplicationFiled: February 9, 2018Publication date: August 15, 2019Inventors: Anant Trivedi, William Holmes, Chandresh Kumar Jain
-
Publication number: 20190108270Abstract: Embodiment for identifying data convergence are presented. First and second sets of data each comprising heterogeneous data are each processed in accordance with a data clustering algorithm so as to obtain a plurality of primary and secondary data clusters, respectively, where each data cluster comprising homogeneous data. The primary and secondary data clusters are analyzed with respect to time to identify convergence of data of the first and second sets of data to first and second topics, respectively. The first and second topics are compared to determine a pattern of data convergence for the first and second data sets.Type: ApplicationFiled: October 5, 2017Publication date: April 11, 2019Inventors: Jonathan Dunne, Karen Forde, William Holmes, Andrew Penrose
-
Publication number: 20190062703Abstract: The present invention provides improved methods For producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.Type: ApplicationFiled: August 27, 2018Publication date: February 28, 2019Applicant: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Patent number: D896009Type: GrantFiled: January 24, 2019Date of Patent: September 15, 2020Inventors: William Holmes, Lisa Holmes